|
Presented at ACC as a Late-Breaking Clinical Trial, VALOR-HCM explores Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive…
|
|
Presented at ACC as a Late-Breaking Clinical Trial, the Cleveland Clinic-led APOLLO trial explores siRNA therapy as a treatment option to help prevent premature heart disease in people with high…
|
|
Access to medical providers can be a challenge for many patients. Dr. Steven Nissen, MD, Chief Academic Officer, describes one approach to help improve patient access to nonprescription statin…
|
|
Dr. Steven Nissen, Chief Academic Officer, Chief Academic Officer, Sydell and Arnold Miller Family Heart & Vascular talks with Dr. Stan Hazen, Co-Section Head, Preventive Cardiology and…
|
|
Dr. Steven Nissen, Chief Academic Officer, Chief Academic Officer, Sydell and Arnold Miller Family Heart & Vascular Institute discusses the latest techniques in treatment of total coronary total…
|
|
Dr. Steven Nissen, Chief Academic Officer, Chief Academic Officer, Sydell and Arnold Miller Family Heart & Vascular Institute talks with Dr. Amar Krishnaswamy interventionalist and expert in…
|
|
Steven Nissen, MD, Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic talks with Dr. Jerry Estep MD, Section Head, Heart Failure and Transplantation…
|
|
Steven Nissen, MD, Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic discusses hypertrophic cardiomyopathy (HCM) with experts: cardiologist Milind…
|